| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...998896C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0098896 |
| P932 | PMC publication ID | 4045772 |
| P698 | PubMed publication ID | 24896564 |
| P5875 | ResearchGate publication ID | 262846504 |
| P50 | author | Ian J Tickle | Q58297284 |
| P2093 | author name string | Hongwei Qi | |
| James F Callahan | |||
| Philip J Day | |||
| Anne Cleasby | |||
| Pamela A Williams | |||
| Thomas G Davies | |||
| Jeff Yon | |||
| Caroline Richardson | |||
| Paris Ward | |||
| Robin Carr | |||
| Thomas Sweitzer | |||
| Jeffrey K Kerns | |||
| Nestor Concha | |||
| P2860 | cites work | Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase | Q24336527 |
| The Protein Data Bank | Q24515306 | ||
| Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress | Q24555749 | ||
| Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex | Q24559743 | ||
| Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity | Q24655442 | ||
| Sequence and structural analysis of BTB domain proteins | Q24812693 | ||
| Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response | Q27647812 | ||
| Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases | Q27657740 | ||
| Insights into strand exchange in BTB domain dimers from the crystal structures of FAZF and Miz1 | Q27661817 | ||
| Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function | Q27673761 | ||
| Serine is a natural ligand and allosteric activator of pyruvate kinase M2 | Q27674495 | ||
| Structural Basis for Cul3 Protein Assembly with the BTB-Kelch Family of E3 Ubiquitin Ligases | Q27675990 | ||
| XDS | Q27860472 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Clustal W and Clustal X version 2.0 | Q27860517 | ||
| Overview of the CCP4 suite and current developments | Q27860782 | ||
| Phasercrystallographic software | Q27860930 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| Scaling and assessment of data quality | Q27861107 | ||
| The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm | Q28216217 | ||
| Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages | Q77749464 | ||
| Targeting the Nrf2 pathway against cardiovascular disease | Q37521075 | ||
| Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice | Q37591945 | ||
| Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. | Q40204136 | ||
| Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation | Q40403963 | ||
| Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products | Q40616566 | ||
| Validation of the multiple sensor mechanism of the Keap1-Nrf2 system | Q41962064 | ||
| Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells | Q42435010 | ||
| Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages | Q43509294 | ||
| Keap calm, and carry on covalently | Q43920761 | ||
| Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets | Q45060228 | ||
| Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane | Q46854767 | ||
| Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. | Q46952116 | ||
| Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema | Q47680966 | ||
| Chiral decalins: preparation from oleanolic acid and application in the synthesis of (-)-9-epi-ambrox | Q53586652 | ||
| Antioxidant-induced modification of INrf2 cysteine 151 and PKC-δ-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. | Q55611195 | ||
| Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants | Q28218883 | ||
| An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements | Q28244853 | ||
| Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3 | Q28267411 | ||
| The cancer chemopreventive actions of phytochemicals derived from glucosinolates | Q28279051 | ||
| Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents | Q28386244 | ||
| Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance | Q28392399 | ||
| Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection | Q28396785 | ||
| The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds | Q28755952 | ||
| Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model | Q28910182 | ||
| Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway | Q29547371 | ||
| Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1 | Q29616500 | ||
| The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase | Q29616502 | ||
| Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers | Q29616503 | ||
| Distinct Cysteine Residues in Keap1 Are Required for Keap1-Dependent Ubiquitination of Nrf2 and for Stabilization of Nrf2 by Chemopreventive Agents and Oxidative Stress | Q29617845 | ||
| Prospective type 1 and type 2 disulfides of Keap1 protein. | Q30371642 | ||
| Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals | Q30497261 | ||
| AstexViewer: a visualisation aid for structure-based drug design | Q31147673 | ||
| Automated protein-ligand crystallography for structure-based drug design | Q33253602 | ||
| Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes | Q33520215 | ||
| Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains | Q33734064 | ||
| Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2 | Q33900511 | ||
| Fragment screening using X-ray crystallography. | Q33934172 | ||
| Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 | ||
| Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. | Q34627230 | ||
| Crystal structure of KLHL3 in complex with Cullin3 | Q34661978 | ||
| Modification of keap1 cysteine residues by sulforaphane | Q34909588 | ||
| Sites of alkylation of human Keap1 by natural chemoprevention agents | Q36282229 | ||
| Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention | Q36376887 | ||
| Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice | Q36402881 | ||
| Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism | Q36642707 | ||
| Functional antioxidant responsive elements. | Q36772872 | ||
| Chemopreventive promise of targeting the Nrf2 pathway | Q36794329 | ||
| Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice | Q37068311 | ||
| The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease | Q37248671 | ||
| Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. | Q37398830 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e98896 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO | |
| P478 | volume | 9 |
| Q28385286 | A generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signaling |
| Q57464878 | A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling |
| Q91725410 | AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes |
| Q38742679 | Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells |
| Q92511933 | Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development |
| Q37714716 | Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2-Related Inflammatory Response. |
| Q99616783 | Bardoxolone conjugation enables targeted protein degradation of BRD4 |
| Q38712952 | Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells |
| Q55256229 | C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape. |
| Q38807055 | CDDO and Its Role in Chronic Diseases. |
| Q35753567 | Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. |
| Q41914517 | Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling |
| Q38822665 | Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response. |
| Q33721819 | Chemical constituents from a Gynostemma laxum and their antioxidant and neuroprotective activities. |
| Q35118710 | Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment |
| Q26827726 | Effect of redox modulating NRF2 activators on chronic kidney disease |
| Q58569406 | Effects of 3-Bromo-4,5-dihydroisoxazole Derivatives on Nrf2 Activation and Heme Oxygenase-1 Expression |
| Q28078928 | Emerging roles of Nrf2 signal in non-small cell lung cancer |
| Q38664878 | Glycosylation of KEAP1 links nutrient sensing to redox stress signaling. |
| Q48774191 | Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs. |
| Q90712638 | In Vitro Biotransformation of the Nrf2 Activator Bardoxolone: Formation of an Epoxide Metabolite That Undergoes Two Novel Glutathione-Mediated Metabolic Pathways: Epoxide Reduction and Oxidative Elimination of Nitrile Moiety |
| Q31057399 | In Situ Observation of Thiol Michael Addition to a Reversible Covalent Drug in a Crystalline Sponge |
| Q49834826 | KEAP1 and Done? Targeting the NRF2 Pathway with Sulforaphane |
| Q39375357 | KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients |
| Q38920601 | Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants. |
| Q90294380 | Molecular Mechanisms of Epigallocatechin-3-Gallate for Prevention of Chronic Kidney Disease and Renal Fibrosis: Preclinical Evidence |
| Q26778356 | Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention |
| Q38705659 | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies |
| Q36277241 | Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway |
| Q91646535 | Nrf2 controls iron homeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin |
| Q89920945 | Potential Applications of NRF2 Modulators in Cancer Therapy |
| Q36144939 | Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. |
| Q93165779 | Progressive Rotavirus Infection Downregulates Redox-Sensitive Transcription Factor Nrf2 and Nrf2-Driven Transcription Units |
| Q35694891 | Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome |
| Q36497820 | Pterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain |
| Q35512908 | RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity |
| Q39270529 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). |
| Q57061808 | Regulation of the NRF2 transcription factor by andrographolide and organic extracts from plant endophytes |
| Q41634246 | Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors |
| Q47903962 | Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress |
| Q38522152 | Structural basis of Keap1 interactions with Nrf2. |
| Q90006408 | Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGF-β Signaling |
| Q33659621 | The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases |
| Q38837451 | The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update |
| Q38889475 | The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases |
| Q90893987 | Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases |
| Q35690117 | Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers |
| Q38289589 | Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review |
Search more.